Rodyklė 
 Ankstesnis 
 Kitas 
 Visas tekstas 
Procedūra : 2018/2185(DEC)
Procedūros eiga plenarinėje sesijoje
Dokumento priėmimo eiga : A8-0135/2019

Pateikti tekstai :

A8-0135/2019

Debatai :

PV 26/03/2019 - 12
CRE 26/03/2019 - 12

Balsavimas :

PV 26/03/2019 - 13.30
Balsavimo rezultatų paaiškinimas

Priimti tekstai :

P8_TA(2019)0271

Diskusijos
Trečiadienis, 2019 m. kovo 27 d. - Strasbūras Atnaujinta informacija

11.2. 2017 m. biudžeto įvykdymo patvirtinimas: Europos vaistų agentūra (EMA) (A8-0135/2019 - Petri Sarvamaa)
Kalbų vaizdo įrašas
 

Dichiarazioni di voto orali

 
  
MPphoto
 

  Alex Mayer (S&D). – Mr President, the GBP 500 million bill because the European Medicines Agency (EMA) could not get out of the 25—year lease on a building in Canary Wharf is deeply regrettable. What a waste. And, to my mind, what a waste to lose highly skilled jobs and research capacity from Britain. The EMA is a jewel in the crown, precisely because it attracts businesses and experts. Over the past two decades, it has been invaluable, simplifying and streamlining medicines regulation, allowing companies to get a medicine authorised in every EU country in one go. Alas for Britain, no more.

A medicines manufacturer in my constituency has already set up a new parallel testing facility within the EU to enable it to sell into European Union countries in the future. More cost, meaning less investment in research and development, and for Britain more delays in getting medicines and a rising bill for medicines, and so less money for our NHS – the opposite of what people thought that they were voting for.

 
Atnaujinta: 2019 m. birželio 28 d.Teisinis pranešimas